Locanabio bolstered its C-suite on Tuesday, appointing executives from CRISPR Therapeutics and Astellas’ Audentes Therapeutics to steer the company’s preclinical pipeline forward. CRISPR Therapeutics’ head of hematology and in vivo research, John Leonard, Ph.D., joins as a chief scientific officer. Locanabio’s chief medical officer will be Edward Conner, M.D., who formerly worked at Audentes Therapeutics, which is now Astellas Gene Therapies.
When it comes to severe neurodegenerative, neuromuscular, and retinal illnesses. In December, the San Diego biotech raised $100 million in a Series B round to develop medicines for myotonic dystrophy, Huntington’s disease, frontotemporal dementia, and other diseases.CEO Jim Burns, Ph.D., in a statement, said, “Their extensive experience in drug discovery and development across multiple therapeutic areas, including rare and neuromuscular diseases, and deep insights into successfully advancing new genetic medicines will be instrumental as we progress and expand the company’s pipeline.”
Conner brings a background in clinical development, translational medicine, and clinical strategy to the table. Conner assisted with clinical development and operations, medical affairs, regulatory, drug safety, and patient advocacy at Audentes, according to Locanabio. Sangamo Therapeutics, Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Roche’s Genentech are among Conner’s previous employers.